It was reported yesterday that Biosortia, a drug discovery company focused on natural microbiomes, has named Dr John Ryals as its new Director.

The new Director is the founder of Metabolon and has served as CEO and board member for 16 years. He has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. Prior to founding Metabolon, Dr Ryals was chief executive officer, president and founder of Paradigm Genetics Inc. He serves on the board of directors at AgBiome and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University.

Ross Youngs, Biosortia's Founder, Chairman and CEO, said, 'It is an honour to have Dr Ryals join the board of directors of Biosortia Pharmaceuticals. John has a proven track record of building professional and scientifically successful biotech companies. John is also a trailblazer who has advanced the understanding of human health with vision, strategy and operational excellence. Biosortia's business of drug discovery using unique capabilities to obtain the hidden drug-like chemistry of microbiome is complemented by Dr Ryals.'